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Pyridoxine dependent epilepsies: new
therapeutical point of view
Raffaele Falsaperla1* and Giovanni Corsello2
Abstract: Pyridoxine dependent epilepsies (PDEs) are rare autosomal recessive disorders with onset in neonatal
period. Seizures are typically not responsive to conventional antiepileptic drugs, but they cease after parental
pyridoxine administration. Atypical forms are characterized partly response to pyridoxine and a late onset of
symptoms (up to the age of three years). Prevalence is variable and it has rarely been described. The genes
involved in PDEs are the gene encoding for the Alpha-aminoadipic-semialdehyde dehydrogenase (ALDH7A1) and
PROSC gene, which encodes a pyridoxal-5-phosphate binding protein. Mutations in the gene encoding for the
pyridoxal-5′-phosphate oxidase enzyme (PNPO) are responsible of a clinical entity similar to PDEs responsive to
pyridoxal-5-phosphate administration not to pyridoxine administration. PDEs diagnosis is often delayed because
they are suspected only after conventional anticonvulsant drugs resistance.
Herein authors aim to present an expert point of view on PDEs in childhood, reviewing the most recent literature
data and proposing a new therapeutical approach for seizures of unknown origin in all those children up to the
age of three years.
Keywords: Pyridoxine dependent epilepsies, Drugs-resistant seizures, Conventional anticonvulsant drugs, Pyridoxine
administration, New therapeutical approach
Main text
Pyridoxine dependent epilepsies (PDEs) are rare auto-
somal recessive disorders characterized by seizures at
neonatal onset not responsive to conventional antiepi-
leptic drugs (CADs), that only cease after parenteral
pyridoxine administration They present with seizures in
neonatal age, not responsive to conventional antiepilep-
tic drugs, that only cease after parenteral pyridoxine
administration. Epidemiology of PDEs has rarely been
described, with a considerable heterogeneity of published
incidence and prevalence. There are few clinical studies
on a cohort basis describing the diagnostic and thera-
peutic management of PDEs in paediatric age. The
disease is usually not suspected before neonatal seizures
are considered resistant to conventional anticonvulsant
drugs. In regards, there is not a standardized diagnostic
work-up for PDEs and this is often the cause for a
delayed diagnosis. Conventional antiepileptic drugs are
used as first-line treatment. We suggest a new therapeu-
tical approach with intravenous pyridoxine, as first line
treatment, in all those children up to the age of three
years, with seizures of unknown origin before starting a
therapy with conventional antiepileptic drugs.
Letter to the editor
Pyridoxine dependent epilepsies (PDEs) are rare
autosomal recessive disorders characterized by seizures
at neonatal onset not responsive to conventional antiepi-
leptic drugs (CADs), that only cease after parenteral
pyridoxine administration [1]. Hunt Ad Jr. et al. first
described PDEs in 1954.
Atypical forms include seizures partly responsive to
pyridoxine, and the late-onset forms, described in chil-
dren up to the age of three years [1–10].
Diagnostic criteria for this condition include: 1) cessa-
tion of clinical and electroencephalographic seizures
following iv administration of 100 mg of pyridoxine; 2)
no seizure recurrence while on long-term treatment [1].
Laboratory tests, including the dosage of alpha-
aminoadipic semihaldeyde (A-AASA), pipecolic acid,
pyridoxine and pyridoxal-5′-phosphate oxidase, and
DNA studies can be useful to confirm the diagnosis.
PDEs epidemiology has rarely been described, with a
considerable heterogeneity; reported birth incidences are
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1:20,000 in Germany, 1:396,000 in Netherlands and
1:783,000 in the UK and Ireland [2].
Mutations in the gene encoding for the alpha-
aminoadipic-semialdehyde dehydrogenase (ALDH7A1)
have been identified at first instance, resulting in the related
enzyme deficiency [3]. Though more than 80 gene muta-
tion variants are been associated with PDEs, only 9 repre-
sent 61% of PDEs mutations. The most common mutation
is the missense p.Glu399Gln in exon 14 representing 30%
of all allele variations. The silent mutation p.Val250Val is
prevalent in the Caucasian population [6]. There are other
clinical entities due to mutations of the gene encoding for
the PNPO, on chromosome 17q21.2, with similar clinical
features of PDEs, but responsive to pyridoxal-5′-phosphate
(PLP) administration, instead of pyridoxine [7]. Recently
PROSC gene, which encodes a PLP binding protein, has
been identified as responsible of PDEs [8]. Some patients
who response to PN or PLP administration don’t have any
known mutation of these genes, suggesting that other not
known yet genes could be involved in PDEs.
On a clinical point of view, literature data report
seizures of various type in PDEs patients, including focal
seizures, generalized tonic-clonic seizures, myoclonia,
and infantile spasms [9]. However, there are few clinical
studies on a cohort basis describing diagnostic and
therapeutic management of PDEs in paediatric age.
Other reports have been published as single cases. This
lack of global vision has caused an under diagnosis of
the condition, as the disease is usually suspected after
neonatal seizures resistance to CADs. There is not a
standardized diagnostic work-up for PDEs and this could
cause further diagnostic delay.
The most common CADs used as first-line treatment in
this condition are: phenobarbital, benzodiazepine, leveti-
racetam, valproic acid, and midazolam; other drugs such
as vigabatrin, phenytoin, ACTH, and dintoine are less fre-
quently used [1]. The wrong diagnosis of the condition
lead to a wrong therapeutic approach, with improper anti-
convulsant drugs administration and related adverse
events. For this reason, according to literature data, we
suggest that an intravenous (IV) pyridoxine test should be
performed in all those children up to the age of three
years, with seizures of unknown origin, as first line treat-
ment, before starting a therapy with conventional anticon-
vulsant drugs. In literature a daily dose of 15–30 mg/Kg
has been recommended for lifelong treatment, and this
should be started after the iv bolus test if positive. If bolus
test is negative, we suggest to give both pyridoxine oral
therapy for few days, for a possible delayed response, and
anticonvulsant therapy. Some patients could need
additional anticonvulsant drugs to control seizures [10].
Moreover the oral dose of pyridoxine at 50 mg/Kg
twice a day for two days has been found as effective as
the iv dose to confirm the diagnosis [4].
Pyridoxine should then be continued as daily treat-
ment, and none of the literature report has described
adverse events for this therapy.
It is important identify children with PDEs for preven-
tion in their mothers’ further pregnancies; in fact
maternal pyridoxine supplementation during pregnancy
is crucial to reduce psychomotor delay in possible
affected foetuses.
Further studies are mandatory to determine short- and
long-term outcome data for children under pyridoxine
treatment and to draft standardized diagnostic and
therapeutic protocols.
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